EBM Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Patel, H.
Right arrow Articles by Vesely, D. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Patel, H.
Right arrow Articles by Vesely, D. L.
Experimental Biology and Medicine 229:521-527 (2004)
© 2004 Society for Experimental Biology and Medicine

ORIGINAL RESEARCH ARTICLE

Combined Treatment with Vessel Dilator and Kaliuretic Hormone in Persons with Congestive Heart Failure

Hamang Patel, John R. Dietz, Ashley Owen, Gloria San Miguel, Michael T. McCormick, Douglas D. Schocken and David L. Vesely1,

U.S.F. Cardiac Hormone Center, Departments of Medicine, Physiology, and Biophysics, University of South Florida Health Sciences Center, and Medicine and Pharmacy Services, James A. Haley Veterans Medical Center, Tampa, Florida 33612

To whom requests for reprints should be addressed at 1 USF Cardiac Hormone Center, 13000 Bruce B. Downs Boulevard, Tampa, FL 33612. E-mail: david.vesely{at}med.va.gov

Vessel dilator and kaliuretic hormone, two cardiovascular peptide hormones, enhance urine flow 2- to 13-fold and 4-fold, respectively, in persons with class III New York Heart Association congestive heart failure (CHF). The natriuresis and diuresis secondary to vessel dilator and kaliuretic hormone are not blunted as are atrial natriuretic peptide and brain natriuretic peptide effects in persons with CHF compared with healthy individuals. The present investigation determined if the two peptide hormones that do not have blunted effects in persons with CHF may have added beneficial effects when given simultaneously to individuals with class III CHF. Together with each at 100 ng/kg of body weight per minute, vessel dilator and kaliuretic hormone increased urine flow rate 3.5-fold (P < 0.05) compared with their 60-min baseline and control CHF subjects’ urine flow rates. Combined, they enhanced the excretion rate of sodium a maximum of 3.6-fold (P < 0.05) with 2.5- and 2-fold enhancement 2 and 3 hrs after infusion. These data indicate that vessel dilator and kaliuretic hormone have diuretic and natriuretic effects when used in combination, but these effects are not additive over their individual effects in persons with CHF.

Key Words: congestive heart failure • atrial natriuretic peptides • treatment • diuresis • natriuresis






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by the Society for Experimental Biology and Medicine.